期刊文献+

阿仑膦酸钠加激素替代治疗绝经后妇女骨量减少的疗效研究 被引量:5

下载PDF
导出
摘要 目的探讨阿仑膦酸钠加激素替代(HRT)、阿仑膦酸钠治疗绝经后妇女骨质疏松、骨量减少的临床疗效及安全性。方法92名绝经后骨质疏松、骨量减少女性随机分为联合组(阿仑膦酸钠加HRT)31例,阿仑膦酸钠组30例,对照组31例,作为期1年随机双盲、安慰剂平行对照研究。用药1年比较治疗前后胫骨骨密度(BMD)和药物副作用。治疗前、治疗后1年应用超声定量骨密度仪进行BMD测定,采用微粒子化学发光免疫分析仪测定血清性激素雌二醇(E2)、促卵泡生成素(FSH)水平,用B超检测子宫内膜厚度、乳腺包块情况。结果联合组、阿仑膦酸钠组治疗1年,胫骨BMD分别增加9.87%、5.69%,与对照组比较差异显著(P<0.01);联合组E2水平升高78.31pmol/L、阿仑膦酸钠组升高2.44pmol/L,FSH水平,联合组下降34.71mIU/ml、阿仑膦酸钠组上升1.72mIU/ml,联合组较对照组差异显著(P<0.01),阿仑膦酸钠组差异不显著(P>0.05);联合组子宫内膜厚度上升了5.35%、阿仑膦酸钠组下降了6.45%,联合组出现乳腺包块平均上升3.13%、阿仑膦酸钠组未出现乳腺包块,较对照组差异不显著(P>0.05)。结论联合组、阿仑膦酸钠组治疗中期能显著改善绝经后骨质疏松、骨量减少妇女胫骨BMD,且对患者子宫、乳腺副作用较轻。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2008年第16期1604-1606,共3页 Chinese Journal of Gerontology
基金 浙江省卫生厅科研项目(No.2005B113)
  • 相关文献

参考文献17

二级参考文献61

  • 1区品中,唐华.应用双能量骨密度仪做骨密度与骨质疏松骨折关系的研究[J].中华骨科杂志,1995,15(5):260-262. 被引量:35
  • 2Kupperman HS, Blatt MBG, Wiesbader H, et al. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices[ J ]. J Clin Endocrionl, 1953,13:688.
  • 3Konincks PHR,Schimdt-gollwitter K. Use of oestradiol valerate in combination with cyproterone acetate to control menopausal symptoms:a review of efficacy,influence on endometrium, on bone metabolism and cardiovascular risk factons[ J]. Eur menopause, 1997,4(2) :49.
  • 4乐杰.妇产科学[M](第6版)[M].北京:人民卫生出版社,2003.121.
  • 5Hasling C, Charles P, Jensen FT, et al. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclical etidronate and an ADFR regime on calcium kinetics and bone mass in potmenopausal women with spinal osteoporosis [J]
  • 6Meschia M, Brincat M, Barbacini P, et al. A Clinical trial on the effects of a combination of elcatonin and conjugated estrogens on vertebral bone mass in early postmenopausal women [J]. Calicified Tissue International, 2003, (53): 17~20
  • 7Svendsen OL, Hassager C, Marslew U, et al. Changes in calcanean bone mineral occurring spontaneously and during hormone replacement therapy in early post-menopausal women [J]. Scandinavian Journal of Clinical and Laboratory Investigation, 2002, (52) : 831
  • 8Adarni S, Baroni MC, Broggini M, et al. Treatment of postmenopausal ostsoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin [J]. Osteoporosis International, 1993, 3 (Suppl. 3): 21~27
  • 9Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss [J]. Calcified Tissue International, 1992, (50): 381-383
  • 10Lyritis GP, Magiasis B, Tsaklakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin [J]. Calcified Tissue International, 1995, (56) : 38-41

共引文献164

同被引文献35

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部